Terms: = Brain cancer AND EML4, ENSG00000143924, 27436 AND Treatment
36 results:
1. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-eml4 in combined treatment of Alectinib and CyberKnife: A case report.
Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
[TBL] [Abstract] [Full Text] [Related]
2. A case of inflammatory myofibroblastic tumor harboring eml4-ALK fusion with a brain metastasis responding to alectinib.
Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
[TBL] [Abstract] [Full Text] [Related]
3. Transformation of NSCLC to SCLC harboring eml4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
4. Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
[TBL] [Abstract] [Full Text] [Related]
5. A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis.
Cheng W; Qian C; Zhang H; Meng Q; Yin JC; Fang S
Anticancer Drugs; 2022 Nov; 33(10):1182-1185. PubMed ID: 35946559
[TBL] [Abstract] [Full Text] [Related]
6. Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China.
Su C; Zhou J; Qiang H; Zhao J; Chang Q; Ji X; Li J; Xie M; Chu T
Int J Cancer; 2023 Jan; 152(1):15-23. PubMed ID: 35579989
[TBL] [Abstract] [Full Text] [Related]
7. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
[TBL] [Abstract] [Full Text] [Related]
8. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract] [Full Text] [Related]
9. Crizotinib for recurring non-small-cell lung cancer with eml4-ALK fusion genes previously treated with alectinib: A phase II trial.
Harada D; Isozaki H; Kozuki T; Yokoyama T; Yoshioka H; Bessho A; Hosokawa S; Takata I; Takigawa N; Hotta K; Kiura K;
Thorac Cancer; 2021 Mar; 12(5):643-649. PubMed ID: 33470536
[TBL] [Abstract] [Full Text] [Related]
10. treatment of brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract] [Full Text] [Related]
11. 68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report.
Tanriverdi O; Tarimer ML; Pak CD; Uylas S; Alkan A; Celik OI; Kilic RM; Zeybek A
J Oncol Pharm Pract; 2021 Jun; 27(4):984-989. PubMed ID: 32830600
[TBL] [Abstract] [Full Text] [Related]
12. An ALK-positive lung adenocarcinoma with gastric and skin metastasis: a case report and literature review.
Duan X; Zhao X; Wang S
Ann Palliat Med; 2021 May; 10(5):5797-5807. PubMed ID: 32819126
[TBL] [Abstract] [Full Text] [Related]
13. ALK-Rearranged Non-Small Cell Lung cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
Itchins M; Lau B; Hudson AL; Westman H; Xia CY; Hayes SA; Howell VM; Rodriguez M; Cooper WA; Wei H; Buckland M; Li BT; Li M; Rathi V; Fox SB; Gill AJ; Clarke SJ; Boyer MJ; Pavlakis N
Oncologist; 2020 Aug; 25(8):641-649. PubMed ID: 32558067
[TBL] [Abstract] [Full Text] [Related]
14. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and eml4-ALK rearrangement.
Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
[TBL] [Abstract] [Full Text] [Related]
15. treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
Hochmair M; Weinlinger C; Schwab S; Naber J; Setinek U; Krenbek D; Urban MH; Fabikan H; Watzka S; Koger R; Fazekas A; Bitterlich E; Valipour A; Burghuber OC
Anticancer Drugs; 2019 Aug; 30(7):e0787. PubMed ID: 31305295
[TBL] [Abstract] [Full Text] [Related]
16. Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
Hochmair M; Weinlinger C; Prosch H
Anticancer Drugs; 2019 Nov; 30(10):1058-1060. PubMed ID: 31033499
[TBL] [Abstract] [Full Text] [Related]
17. Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With eml4-ALK Fusion Variant 5 Refractory to ALK Inhibitors.
Gong J; Gregg JP; Ma W; Yoneda K; Moore EH; Daly ME; Zhang Y; Williams MJ; Li T
J Natl Compr Canc Netw; 2019 Apr; 17(4):297-301. PubMed ID: 30959466
[TBL] [Abstract] [Full Text] [Related]
18. Updated Efficacy and Safety Data and Impact of the eml4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract] [Full Text] [Related]
19. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung cancer.
Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
[TBL] [Abstract] [Full Text] [Related]
20. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract] [Full Text] [Related]
[Next]
